Twenty-two patients with advanced non–small-cell lung cancer (NSCLC) received first-line treatment, and (18F-FDG) positron emission tomography (PET) and computed tomography (CT) were performed before and after therapy. A trend was shown on FDG-PET for responders to treatment after 2 weeks in terms of progression-free survival (PFS) and overall survival (OS). Early metabolic responders had a better outcome. Background: This study aimed to demonstrate that patients who exhibit a tumor metabolic response to first-line chemotherapy seen on FDG-PET and computed tomography (CT) would survive longer than those who did not show such a response, comparing this evaluation with the morphologic response seen on CT. Patients and Methods: Images were acquired in 22 consecutive patients with advanced non–small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. FDG-PET was performed within 4 weeks before (PET1) and 2 weeks after starting treatment (PET2). Similarly, CT (CT1) was performed at baseline and then every 2 cycles (6 weeks) during treatment (CT2). Responders and nonresponders were identified with FDG-PET, and metabolic response was then compared with morphologic changes detected by spiral CT. Results: Twenty-one of 22 patients completed this study. In terms of progression-free survival (PFS) (45 vs. 22.2 weeks) and overall survival (OS) (77 vs. 47.7 weeks), we observed a trend that was not statistically significant for patients whose response after 2 weeks of treatment was seen on FDG-PET (P .22 for PFS; P .15 for OS). Conclusion: Patients with advanced NSCLC who had a positive outcome, as evidenced by prolonged survival, were those who showed a tumor metabolic response seen on FDG-PET.

Early Response to Chemotherapy in Patients With Non-Small-Cell Lung Cancer Assessed by [18F]-Fluoro-Deoxy-D-Glucose Positron Emission Tomography and Computed Tomography.

NOVELLO, Silvia;GIAJ LEVRA, Matteo;SOLITRO, Federica;VELTRI, Andrea;SCAGLIOTTI, Giorgio Vittorio
2013-01-01

Abstract

Twenty-two patients with advanced non–small-cell lung cancer (NSCLC) received first-line treatment, and (18F-FDG) positron emission tomography (PET) and computed tomography (CT) were performed before and after therapy. A trend was shown on FDG-PET for responders to treatment after 2 weeks in terms of progression-free survival (PFS) and overall survival (OS). Early metabolic responders had a better outcome. Background: This study aimed to demonstrate that patients who exhibit a tumor metabolic response to first-line chemotherapy seen on FDG-PET and computed tomography (CT) would survive longer than those who did not show such a response, comparing this evaluation with the morphologic response seen on CT. Patients and Methods: Images were acquired in 22 consecutive patients with advanced non–small-cell lung cancer (NSCLC) randomized to receive carboplatin/paclitaxel/sorafenib or placebo. FDG-PET was performed within 4 weeks before (PET1) and 2 weeks after starting treatment (PET2). Similarly, CT (CT1) was performed at baseline and then every 2 cycles (6 weeks) during treatment (CT2). Responders and nonresponders were identified with FDG-PET, and metabolic response was then compared with morphologic changes detected by spiral CT. Results: Twenty-one of 22 patients completed this study. In terms of progression-free survival (PFS) (45 vs. 22.2 weeks) and overall survival (OS) (77 vs. 47.7 weeks), we observed a trend that was not statistically significant for patients whose response after 2 weeks of treatment was seen on FDG-PET (P .22 for PFS; P .15 for OS). Conclusion: Patients with advanced NSCLC who had a positive outcome, as evidenced by prolonged survival, were those who showed a tumor metabolic response seen on FDG-PET.
2013
2013 May;14(3(
230
237
Novello S; Vavalà T; Giaj Levra M; Solitro F; Pelosi E; Veltri A; Scagliotti GV.
File in questo prodotto:
File Dimensione Formato  
Early response_Elsevier Enhanced Reader.pdf

Accesso riservato

Tipo di file: PDF EDITORIALE
Dimensione 4.73 MB
Formato Adobe PDF
4.73 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2318/130154
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 21
  • ???jsp.display-item.citation.isi??? 18
social impact